SCHEMBL26205918

SCHEMBL26205918

Cc1ccc(NC2=CC(=O)N(c3cc(F)c(O)c(F)c3)C2=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ G6PD P11413 1/20 0.39
▸ ALDH1A1 P00352 6/20 0.38
▸ KDM4E B2RXH2 4/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ MAPT P10636 3/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ APP P05067 2/20 0.38
▸ RPS6KA3 P51812 1/20 0.36
▸ POLB P06746 3/20 0.36
▸ HPGD P15428 2/20 0.36
▸ TP53 P04637 2/20 0.36
▸ LMNA P02545 2/20 0.36
▸ TDP2 O95551 1/20 0.36
▸ NSD2 O96028 1/20 0.36
▸ MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24430074 0.91 MEN1 (0.50) MEN1KMT2AL3MBTL1GAAG6PD
SCHEMBL24430029 0.89 MEN1 (0.54) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL24437423 0.86 MEN1 (0.50) MEN1KMT2AL3MBTL1GAAALDH1A1
SCHEMBL24430115 0.82 MEN1 (0.44) MEN1KMT2AALDH1A1KDM4ERPS6KA3
SCHEMBL24430113 0.81 MEN1 (0.54) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL24437348 0.81 MEN1 (0.43) MEN1KMT2AALDH1A1KDM4E
SCHEMBL24430075 0.81 KMT2A (0.45) MEN1KMT2AL3MBTL1GAAG6PD
SCHEMBL24430080 0.80 MAPT (0.37) MEN1KMT2AL3MBTL1GAAG6PD
SCHEMBL26205855 0.80 MEN1 (0.52) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL24430026 0.80 KMT2A (0.52) MEN1KMT2AALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease HMOX1, GLS, HMOX2 MEN1 4171/4885KMT2A 2088/4885L3MBTL1 1613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback